Relief Therapeutics Holding SA (SWX:RLF)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions CHF. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 12, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	32	53	25	132	274	873
Market Cap Growth	111.56%	111.56%	-81.09%	-51.90%	-68.59%	41215.19%
Enterprise Value	19	44	17	106	263	874
Last Close Price	2.56	4.21	1.99	12.00	24.88	107.60
PS Ratio	3.82	6.27	4.14	21.70	82.61	-
PB Ratio	0.88	1.44	0.48	0.91	1.51	13.03
P/TBV Ratio	5.71	9.36	-	-	-	24.10
EV/Sales Ratio	2.29	5.29	2.77	17.46	79.33	-
Debt / Equity Ratio	0.06	0.06	0.08	0.03	0.02	0.01
Asset Turnover	0.13	0.13	0.05	0.03	0.02	-
Inventory Turnover	3.22	3.22	4.90	4.05	3.84	-
Quick Ratio	3.43	3.43	2.52	2.01	2.41	5.73
Current Ratio	3.95	3.95	2.65	2.11	2.79	7.00
Return on Equity (ROE)	-38.52%	-38.52%	-99.35%	-31.07%	-27.92%	-19.25%
Return on Assets (ROA)	-7.35%	-7.35%	-9.36%	-9.92%	-12.98%	-24.72%
Return on Capital (ROIC)	-9.99%	-9.99%	-12.03%	-13.02%	-16.87%	-28.82%
Earnings Yield	-53.18%	-32.42%	-393.43%	-38.49%	-12.65%	-0.90%
FCF Yield	-9.10%	-5.55%	-72.36%	-18.31%	-13.02%	-2.09%
Buyback Yield / Dilution	-6.71%	-6.71%	-11.18%	-17.67%	-48.89%	-14.70%

Updated Apr 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.